

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

Atropine for Organophosphate Poisoning in the Pre-Hospital Setting: Clinical Effectiveness and Guidelines

Service Line: Rapid Response Service
Version: 1.0
Publication Date: May 23, 2019
Report Length: 5 Pages

Authors: Camille Dulong, Aleksandra Grobelna

Cite As: Atropine for organophosphate poisoning in the pre-hospital setting: clinical effectiveness and guidelines. Ottawa: CADTH; 2019 May. (CADTH rapid response report: summary of abstracts).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Research Questions

1. What is the clinical effectiveness of various doses of atropine for pre-hospital treatment of organophosphate poisoning?
2. What are the evidence-based guidelines regarding pre-hospital treatment of patients experiencing organophosphate poisoning?

Key Findings

No relevant literature was identified regarding the clinical effectiveness of various doses of atropine for pre-hospital treatment of organophosphate. Additionally, no evidence-based guidelines were found regarding pre-hospital treatment of patients experiencing organophosphate poisoning.

Methods

A limited literature search was conducted by an information specialist on key resources including PubMed, the Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were atropine and organophosphate poisoning. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between Jan 1, 2014 and May 14, 2019. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	Patients experiencing organophosphate poisoning in the pre-hospital setting
Intervention	Q1: Atropine Q2: Treatment for organophosphate poisoning
Comparator	Q1: Other doses of atropine; other interventions for organophosphate poisoning Q2: No comparator
Outcomes	Q1: Clinical effectiveness (e.g., mortality, respiratory failure, heart injury, liver injury, brain injury, poisoning complications, adverse events) Q2: Best practice recommendations, guidelines
Study Designs	Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, and evidence-based guidelines

Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

No relevant literature, including evidence-based guidelines, was identified regarding the pre-hospital treatment of organophosphate poisoning and the clinical effectiveness of various atropine doses in pre-hospital settings.

References of potential interest are provided in the appendix.

Overall Summary of Findings

No relevant literature was identified regarding the clinical effectiveness of atropine in various doses for organophosphate poisoning in a pre-hospital setting. No evidence-based guidelines were identified regarding the treatment of organophosphate poisoning in a pre-hospital setting.

References Summarized

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

No literature identified.

Randomized Controlled Trials

No literature identified.

Non-Randomized Studies

No literature identified.

Guidelines and Recommendations

No literature identified.

Appendix — Further Information

Non-Randomized Studies

Pre-Hospital Setting

1. Karakus A, Celik MM, Karcioglu M, Tuzcu K, Erden ES, Zeren C. Cases of organophosphate poisoning treated with high-dose of atropine in an intensive care unit and the novel treatment approaches. *Toxicol Ind Health*. 2014 Jun;30(5):421-425.
[PubMed: PM23012340](#)

Alternative Intervention

2. Liu HX, Liu CF, Yang WH. Clinical study of continuous micropump infusion of atropine and pralidoxime chloride for treatment of severe acute organophosphorus insecticide poisoning. *J Chin Med Assoc*. 2015 Dec;78(12):709-713.
[PubMed: PM26441220](#)

Review Articles

3. Bajracharya SR, Prasad PN, Ghimire R. Management of organophosphorus poisoning. *J Nepal Health Res Council*. 2016 Sep;14(34):131-138.
[PubMed: PM28327676](#)